- Home
- DMAC vs NB Comparison
DMAC vs NB Comparison
Compare DMAC & NB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- NB
- Stock Information
- Founded
- DMAC 2000
- NB 1987
- Country
- DMAC United States
- NB United States
- Employees
- DMAC N/A
- NB N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- NB Metal Mining
- Sector
- DMAC Health Care
- NB Basic Materials
- Exchange
- DMAC Nasdaq
- NB Nasdaq
- Market Cap
- DMAC 310.1M
- NB 291.3M
- IPO Year
- DMAC N/A
- NB N/A
- Fundamental
- Price
- DMAC $6.97
- NB $5.58
- Analyst Decision
- DMAC Strong Buy
- NB Strong Buy
- Analyst Count
- DMAC 3
- NB 2
- Target Price
- DMAC $12.33
- NB $4.50
- AVG Volume (30 Days)
- DMAC 443.2K
- NB 3.2M
- Earning Date
- DMAC 11-12-2025
- NB 09-11-2025
- Dividend Yield
- DMAC N/A
- NB N/A
- EPS Growth
- DMAC N/A
- NB N/A
- EPS
- DMAC N/A
- NB N/A
- Revenue
- DMAC N/A
- NB N/A
- Revenue This Year
- DMAC N/A
- NB N/A
- Revenue Next Year
- DMAC N/A
- NB N/A
- P/E Ratio
- DMAC N/A
- NB N/A
- Revenue Growth
- DMAC N/A
- NB N/A
- 52 Week Low
- DMAC $3.19
- NB $1.27
- 52 Week High
- DMAC $7.49
- NB $5.90
- Technical
- Relative Strength Index (RSI)
- DMAC 66.23
- NB 72.04
- Support Level
- DMAC $6.83
- NB $4.16
- Resistance Level
- DMAC $7.41
- NB $4.63
- Average True Range (ATR)
- DMAC 0.42
- NB 0.40
- MACD
- DMAC 0.06
- NB 0.09
- Stochastic Oscillator
- DMAC 77.88
- NB 81.61
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.